☰

Roy Maute, Ph.D. - Publications

Affiliations: 
2013 Genetics and Development Columbia University, New York, NY 
Area:
Molecular Biology, Biochemistry
Tree Info Similar researchers PubMed Report error

21 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Lakhani NJ, Patnaik A, Liao JB, Moroney JW, Miller DS, Fleming GF, Axt M, Wang YV, Agoram B, Volkmer J, Maute R, Schroeder A, Chico I, Chao M, Takimoto CH, et al. A phase Ib study of the anti-CD47 antibody magrolimab with the PD-L1 inhibitor avelumab (A) in solid tumor (ST) and ovarian cancer (OC) patients. Journal of Clinical Oncology. 38: 18-18. DOI: 10.1200/Jco.2020.38.5_Suppl.18  0.541
2020 Fisher GA, Lakhani NJ, Eng C, Hecht JR, Bendell JC, Philip PA, O'Dwyer PJ, Johnson B, Kardosh A, Ippolito TM, Wang YV, Agoram B, Volkmer J, Maute R, Chico I, et al. A phase Ib/II study of the anti-CD47 antibody magrolimab with cetuximab in solid tumor and colorectal cancer patients. Journal of Clinical Oncology. 38: 114-114. DOI: 10.1200/Jco.2020.38.4_Suppl.114  0.323
2020 Agoram B, Jin C, Maute R, Takimoto CH, Chao M, Sallman DA. Pharmacokinetic (PK)-pharamcodynamic (PD) analysis and receptor occupancy data to support every other week maintenance dosing of magrolimab in combination with azacitidine in MDS/AML patients. Journal of Clinical Oncology. 38: e15098-e15098. DOI: 10.1200/Jco.2020.38.15_Suppl.E15098  0.342
2020 Sallman DA, Al Malki M, Asch AS, Lee DJ, Kambhampati S, Donnellan WB, Bradley TJ, Vyas P, Jeyakumar D, Marcucci G, Komrokji RS, Van Elk J, Lin M, Maute R, Volkmer J, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. Journal of Clinical Oncology. 38: 7507-7507. DOI: 10.1200/Jco.2020.38.15_Suppl.7507  0.363
2019 Maute RL, Chen JY, Marjon KD, Duan J, Choi T, Chao M, Takimoto CH, Agoram B, Volkmer J. Translational Study of Cell Surface Proteins in Non-Hodgkin Lymphoma Patients Treated with the First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Rituximab Blood. 134: 5229-5229. DOI: 10.1182/Blood-2019-127526  0.771
2018 Barkal AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, Barkal LJ, ... ... Maute RL, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy. Nature Immunology. 19: 76-84. PMID 29180808 DOI: 10.1038/S41590-017-0004-Z  0.614
2017 Barkal, AA, Weiskopf K, Kao KS, Gordon SR, Rosental B, Yiu YY, George BM, Markovic M, Ring NG, Tsai JM, McKenna KM, Ho PY, Cheng RZ, Chen JY, ... ... Maute RL, et al. Engagement of MHC class I by the inhibitory receptor LILRB1 suppresses macrophages and is a target of cancer immunotherapy Nature Immunology. PMID 29180808 DOI: 10.1038/s41590-017-0004-z  0.464
2017 Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. PMID 28514441 DOI: 10.1038/Nature22396  0.733
2016 Mayer AT, Natarajan A, Gordon S, Maute R, McCracken M, Ring A, Weissman I, Gambhir SS. Practical ImmunoPET radiotracer design considerations for human immune checkpoint imaging. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. PMID 27980047 DOI: 10.2967/Jnumed.116.177659  0.774
2016 Pascolutti R, Sun X, Kao J, Maute RL, Ring AM, Bowman GR, Kruse AC. Structure and Dynamics of PD-L1 and an Ultra-High-Affinity PD-1 Receptor Mutant. Structure (London, England : 1993). PMID 27618663 DOI: 10.1016/J.Str.2016.06.026  0.742
2016 Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer JP, Liu J, Lim JS, Yang D, Seitz G, Nguyen T, Wu D, Jude K, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. The Journal of Clinical Investigation. PMID 27294525 DOI: 10.1172/Jci81603  0.744
2016 Gordon SR, Maute R, Mayer A, McCracken M, Natarajan A, Guo N, Kimura R, Tsai JM, Manglik A, Kruse A, Gambhir S, Weissman IL, Ring AM. Abstract B101: Engineered PD-1 variants as immunotherapies for cancer Cancer Immunology Research. 4. DOI: 10.1158/2326-6074.Cricimteatiaacr15-B101  0.803
2015 Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, Gambhir SS, Weissman IL, Ring AM. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proceedings of the National Academy of Sciences of the United States of America. 112: E6506-14. PMID 26604307 DOI: 10.1073/Pnas.1519623112  0.758
2015 Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, Gambhir SS, Weissman IL, Ring AM. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging Proceedings of the National Academy of Sciences. PMID 26604307  0.536
2014 Schneider C, Setty M, Holmes AB, Maute RL, Leslie CS, Mussolin L, Rosolen A, Dalla-Favera R, Basso K. MicroRNA 28 controls cell proliferation and is down-regulated in B-cell lymphomas. Proceedings of the National Academy of Sciences of the United States of America. 111: 8185-90. PMID 24843176 DOI: 10.1073/Pnas.1322466111  0.436
2014 Maute RL, Dalla-Favera R, Basso K. RNAs with multiple personalities. Wiley Interdisciplinary Reviews. Rna. 5: 1-13. PMID 24039180 DOI: 10.1002/Wrna.1193  0.387
2014 Weiskopf K, Ring AM, Guo N, Schnorr PJ, Maute RL, Volkmer J, Weissman IL. Direct SIRPa Blockade Augments Macrophage Responses to Therapeutic Anticancer Antibodies Blood. 124: 2729-2729. DOI: 10.1182/Blood.V124.21.2729.2729  0.787
2013 Maute RL, Schneider C, Sumazin P, Holmes A, Califano A, Basso K, Dalla-Favera R. tRNA-derived microRNA modulates proliferation and the DNA damage response and is down-regulated in B cell lymphoma. Proceedings of the National Academy of Sciences of the United States of America. 110: 1404-9. PMID 23297232 DOI: 10.1073/Pnas.1206761110  0.462
2010 Schneider C, Maute RL, Sumazin P, Brahmachary M, Setty M, Pasqualucci L, Rosolen A, Leslie C, Basso K, Dalla-Favera R. MiR-28 Silencing In Germinal Center-Derived Lymphomas Blood. 116: 703-703. DOI: 10.1182/Blood.V116.21.703.703  0.431
2009 Basso K, Sumazin P, Morozov P, Schneider C, Maute RL, Kitagawa Y, Mandelbaum J, Haddad J, Chen CZ, Califano A, Dalla-Favera R. Identification of the human mature B cell miRNome. Immunity. 30: 744-52. PMID 19446474 DOI: 10.1016/J.Immuni.2009.03.017  0.428
2007 Basso K, Morozov P, Kitagawa Y, Maute RL, Rosolen A, Chen C, Califano A, Dalla-Favera R. Investigating Mature B-Cell Lymphomas by MicroRNA Profiling. Blood. 110: 3185-3185. DOI: 10.1182/Blood.V110.11.3185.3185  0.411
Show low-probability matches.